亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Safety and efficacy of T-614 in the treatment of patients with active rheumatoid arthritis: a double blind, randomized, placebo-controlled and multicenter trial.

医学 血沉 安慰剂 痹症科 类风湿性关节炎 随机对照试验 人口 关节炎 临床试验 内科学 外科 胃肠病学 病理 环境卫生 替代医学
作者
Huijing Huang,Jialin Teng,Chunde Bao,Xinghai Han,Lingyun Sun,Jiang-hua Xu,Xing-Fu Li,Huaxiang Wu
出处
期刊:PubMed 卷期号:121 (7): 615-9 被引量:31
标识
DOI:10.1097/00029330-200804010-00008
摘要

A novel anti-rheumatic drug, T-614, has been shown to have an anti-inflammatory effect and to improve abnormal immunological findings in rheumatoid arthritis (RA). To assess the safety and efficacy of T-614 versus placebo in patients with active RA we conducted a 24-week clinical study in 280 Chinese patients.In a multicenter, randomized, double blind, placebo controlled study, 280 patients were randomly assigned to receive placebo (n = 95) or T-614 at 50 mg (n = 93) or 25 mg (n = 92) daily. Active disease was defined by 4 of the following 5 criteria: >or= 5 tender joints, >or= 3 swollen joints, morning stiffness lasting for >or= 60 minutes, and Westergren erythrocyte sedimentation rate (ESR) >or= 28 mm/h, the assessment of pain at the rest by patient as moderate or severe. Clinical and laboratory parameters were analyzed at baseline, 2, 4, 6, 12, 18 and 24 weeks. The primary efficacy variable at week 24 was the American College of Rheumatology (ACR) response rate using the intent-to-treat population.The ACR response rate was significantly higher in the T-614 treatment group compared with the placebo group within 8 weeks after the initiation of treatment. After 24 weeks, the 25 mg/d and 50 mg/d dosage groups and the placebo group showed 39.13%, 61.29% and 24.21% in ACR20 and 23.91%, 31.18% and 7.37% in ACR50, respectively. A time-response in ACR response was observed, with clear superiority for the 25 mg/d and 50 mg/d dosage groups compared to placebo (P < 0.0001), and the 50 mg/d dose compared to the 25 mg/d dose (P < 0.05) when using the ACR response analyses after 24 weeks. ESR and c-reactive protein (CRP) were significantly different in the treatment groups after 24 weeks. The incidence of adverse events (AEs) was not significantly higher with T-614 than with placebo, but upper abdominal discomfort, leucopenia, elevated serum alanine aminotransferase (sALT), skin rash and/or pruritus were more common in the 50 mg and 25 mg dosage groups.T-614, a new slow-acting drug, is effective in treatment of rheumatoid arthritis and is well tolerated.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
36秒前
38秒前
40秒前
量子星尘发布了新的文献求助10
48秒前
KSung完成签到 ,获得积分10
54秒前
58秒前
临河盗龙发布了新的文献求助30
1分钟前
临河盗龙完成签到,获得积分20
1分钟前
zhanglq完成签到,获得积分10
1分钟前
1分钟前
studystudy完成签到,获得积分10
1分钟前
激动的似狮完成签到,获得积分10
1分钟前
自律发布了新的文献求助10
1分钟前
NexusExplorer应助fukase采纳,获得10
1分钟前
自律完成签到,获得积分10
1分钟前
量子星尘发布了新的文献求助10
1分钟前
2分钟前
fukase完成签到,获得积分10
2分钟前
fukase发布了新的文献求助10
2分钟前
jiangjiang完成签到 ,获得积分10
2分钟前
2分钟前
科研通AI2S应助科研通管家采纳,获得10
2分钟前
tsttst完成签到,获得积分10
2分钟前
2分钟前
2分钟前
3分钟前
Qiuyajing完成签到,获得积分10
3分钟前
3分钟前
星辰大海应助兴奋的嘉懿采纳,获得10
3分钟前
祖之微笑发布了新的文献求助10
3分钟前
兴奋的嘉懿完成签到,获得积分20
3分钟前
量子星尘发布了新的文献求助10
3分钟前
3分钟前
3分钟前
3分钟前
3分钟前
葱饼完成签到 ,获得积分10
4分钟前
香蕉觅云应助sunshihaoya采纳,获得10
4分钟前
4分钟前
4分钟前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3976665
求助须知:如何正确求助?哪些是违规求助? 3520756
关于积分的说明 11204743
捐赠科研通 3257502
什么是DOI,文献DOI怎么找? 1798733
邀请新用户注册赠送积分活动 877897
科研通“疑难数据库(出版商)”最低求助积分说明 806629